Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Robert T. Brodell MD, FAAD Editor-in-Chief

Eliot N. Mostow MD, MPH Associate Editor

Sarah L. Chamlin MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · June 19, 2024

Safety and Efficacy of Dupilumab in Children With Atopic Dermatitis Aged 6 Months to 5 Years

American Journal of Clinical Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Sarah Chamlin MD

American Journal of Clinical Dermatology

Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study

Am J Clin Dermatol 2024 May 14;[EPub Ahead of Print], AS Paller, EC Siegfried, EL Simpson, MJ Cork, R Sidbury, IH Chen, FA Khokhar, J Xiao, A Dubost-Brama, A Bansal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Safety and Efficacy of Dupilumab in Children With Atopic Dermatitis Aged 6 Months to 5 Years

Additional Info

Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study

Further Reading

Impact of AJCC Eighth Edition Staging Changes on Sentinel Lymph Node Biopsy Practices Among Patients With Melanoma

Outcomes of Using Wound Closure Techniques After Wide Excision of Hidradenitis Suppurativa Lesions

Rebound Growth of Infantile Hemangiomas After Discontinuation of Treatment With Propranolol vs Atenolol

Allergic Contact Cheilitis/Stomatitis Owing to Beverages and Food

Assessing Skin Cancer Diagnosis Accuracy by Lesion Type, Physician Experience, and Examination Method

Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Recently Updated